The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature

Blood

Volumn 123, Issue 18, 2014, Pages 2893-2894

  Manso, Rebeca ^a   Rojo, Federico ^a   Rodríguez Pinilla, Socorro M ^a   Sánchez Beato, Margarita ^b   Gómez, Sagrario ^b   Monsalvo, Silvia ^c   Llamas, Pilar ^c   Cereceda, Laura ^d   Piris, Miguel A ^d   Mollejo, Manuela ^e   Menàrguez, Javier ^f   Alves, Javier ^g   García Cosio, Mónica ^h  

^a Fundacion Jimenez Diaz   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL VIRGEN DE LA SALUD   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN P50; PROTEIN P52; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VINCRISTINE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PERIPHERAL T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

CODON; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MUTATION; PROGNOSIS; RHOA GTP-BINDING PROTEIN; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84903199396     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-555946     Document Type: Letter

References (9)

1. Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166-170.
2. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171-175.
3. Roncador G, García Verdes-Montenegro JF, Tedoldi S, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica. 2007;92(8):1059-1066. (Pubitemid 350144212)
4. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol. 1999;147(5):1009-1022.
5. Murga C, Zohar M, Teramoto H, Gutkind JS. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene. 2002;21(2):207-216. (Pubitemid 34102129)
6. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogenactivated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood. 2009;113(4):893-901.
7. Yan ZX, Wu LL, Xue K, et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma [published online ahead of print October 9, 2013]. Leukemia.
8. Martín-Sánchez E, Rodríguez-Pinilla SM, Sánchez-Beato M, et al. Simultaneous inhibition of pan- phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica. 2013;98(1):57-64.
9. Odqvist L, Sánchez-Beato M, Montes-Moreno S, et al. NIK controls classical and alternative NF-kB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res. 2013;19(9):2319-2330.